Genvoya Crushed Dose — Competitive Intelligence Brief

Genvoya Crushed Dose (Genvoya Crushed Dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (integrase inhibitor + NRTI + NtRTI + booster). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (integrase inhibitor + NRTI + NtRTI + booster) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Genvoya Crushed Dose (Genvoya Crushed Dose) — Johns Hopkins University. Genvoya is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Genvoya Crushed Dose TARGET	Genvoya Crushed Dose	Johns Hopkins University	marketed	Antiretroviral combination (integrase inhibitor + NRTI + NtRTI + booster)	HIV integrase, HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase
DTG/ABC/3TC	DTG/ABC/3TC	Harvard School of Public Health (HSPH)	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (integrase inhibitor + NRTI + NtRTI + booster) class)

1. Johns Hopkins University · 1 drug in this class